Partner Steve Maebius contributed an article to Pharmaceutical Executive, “New Challenge to IP Innovation,” on August 31, 2016. The article provided an overview of the use of Inter Partes Reviews (IPRs) in the pharmaceutical industry, for both generic and originator companies. Maebius discussed the findings of a survey that analyzed 111 IPR filings by generic drug companies against pharmaceutical patents and highlighted key considerations for originator companies.
Author(s)
Related Insights
18 March 2025
Foley Viewpoints
No Action Letter – Regulation D Rule 506(c)
The SEC now permits public marketing of private placements, without burdensome investor wealth verification requirements, if the investment is big enough.
18 March 2025
Energy Current
Mexican Government Proposes Bill to Regulate the Energy Sector
On February 4, 2025, Mexican President Claudia Sheinbaum submitted a bill to the Mexican Senate to revoke, issue, and amend various energy laws in accordance with the constitutional amendments passed in December 2024.
18 March 2025
Innovative Technology Insights
The Symbiotic Future of Quantum Computing and AI
While quantum computers remain in their infancy, AI could provide a bridge to unlocking their potential.